Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Orexo enters reimbursement agreement with UnitedHealth Group and OptumRx for ZUBSOLV-DJ


Wednesday, 12 Mar 2014 03:47am EDT 

Orexo AB:Enters a multi-year agreement with UnitedHealth Group Inc and OptumRx providing preferred coverage and reimbursement of ZUBSOLV-DJ.Says under the agreement, ZUBSOLV will be given preferred, Tier 2 brand status on UnitedHealth Group commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid dependence through June 30.Says as of July 1 ZUBSOLV will become the only buprenorphine/naloxone combination product on all of UnitedHealth's closed and managed health plan formularies, inclusive of all brand and generic formulations. 

Company Quote

102.55
-0.13 -0.13%
26 Dec 2014